Organization | EBEWE Pharma

EBEWE Pharma Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: Unterach am Attersee Austria (1934)

Status: Acquired by Sandoz (2009) → now Novartis (1996)

Organization Overview

First Clinical Trial

2004

NCT00911807

First Marketed Drug

2008

vinorelbine (navelbine)

First NDA Approval

None

Last Known Activity

2009

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EBEWE Neuro Pharma | EBEWE PHARMA | Ebewe Pharma GmbH

Active Ingredients

Marketed Drugs (3)

epirubicin (ellence) (2009)

fluorouracil (efudex) (2008)

vinorelbine (navelbine) (2008)

Drugs in Phase 4 Trials (2)

cenegermin-bkbj (oxervate) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 3 Trials (4)

capecitabine (xeloda) (1 trial)

docetaxel (taxotere) (1 trial)

epirubicin (ellence) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (2)

donepezil (aricept) (1 trial)

porcine brain-derived peptide preparation (cerebrolysin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 2)

Breast Neoplasms (Phase 3)

Dementia (Phase 4)

Dementia, Vascular (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 8